Journal of minimally invasive gynecology
-
J Minim Invasive Gynecol · Sep 2014
Randomized Controlled TrialEffects of peritoneal ropivacaine nebulization for pain control after laparoscopic gynecologic surgery.
To evaluate the effects of peritoneal cold nebulization of ropivacaine on pain control after gynecologic laparoscopy. ⋯ Cold nebulization of ropivacaine before surgery reduced postoperative pain and morphine consumption and was associated with earlier walking without assistance.
-
J Minim Invasive Gynecol · Sep 2014
Multicenter StudyPredictors of surgical site infection in women undergoing hysterectomy for benign gynecologic disease: a multicenter analysis using the national surgical quality improvement program data.
To estimate the rate and predictors of surgical site infection (SSI) after hysterectomy performed for benign indications and to identify any association between SSI and other postoperative complications. ⋯ SSI occurred more often after abdominal hysterectomy than laparoscopic hysterectomy performed to treat benign gynecologic disease. SSI was associated with increased postoperative complications but not mortality. Several risk factors for SSI after each abdominal and laparoscopic hysterectomy were identified in this study.
-
J Minim Invasive Gynecol · Sep 2014
Multicenter StudyThree-year outcome of the Halt trial: a prospective analysis of radiofrequency volumetric thermal ablation of myomas.
To analyze the clinical success of radiofrequency volumetric thermal ablation (RFVTA) at 3-year follow-up in terms of subject responses to validated questionnaires and surgical repeat intervention to treat myomas. ⋯ RFVTA of uterine myomas resulted in sustained relief from myoma symptoms and continued improvement in health-related quality of life through 36 months after ablation. The low repeat intervention data through 36 months is a positive outcome for patient well-being.
-
J Minim Invasive Gynecol · Sep 2014
ReviewManagement of complications encountered with Essure hysteroscopic sterilization: a systematic review.
Essure hysteroscopic sterilization has been US Food and Drug Administration-approved in the United States since 2002. Complications associated with the Essure device include improper placement (malpositioning), unintended pregnancy, pain, infection, and nickel allergy. The rarity of complications, compounded by underreporting, makes it difficult to determine best practices insofar as management. This systematic review synthesizes the national and global experience with management of Essure-related complications and suggests treatment options when data allow.